Active	Status	Sponsor type	Region	Phase	Filter
6 Active 11 Inactive 17 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

6 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Foa, Roberto
GIMEMA, NCT01361438: De Novo Adult Philadelphia Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) Patients	Active, not recruiting	2	60	Europe	Total therapy approach	Gruppo Italiano Malattie EMatologiche dell'Adulto	ALL Ph Positive	10/14	12/20
NCT02232386 / 2014-002714-23: Phase 2 Study to Assess Activity & Safety of Front-line Ibrutinib + Rituximab in Unfit Chronic Lymphocytic Leukemia	Completed	2	156	Europe	Ibrutinib, Rituximab	Gruppo Italiano Malattie EMatologiche dell'Adulto	Chronic Lymphocyte Leukemia, Adult Patients	04/18	04/24
VeRitAs, NCT03455517 / 2018-000877-61: Activity and Safety of Front-line Venetoclax and Rituximab in Young and Fit Patients With Chronic Lymphocytic Leukemia	Completed	2	77	Europe	Venetoclax, Rituximab	Gruppo Italiano Malattie EMatologiche dell'Adulto	Chronic Myeloid Leukemia	09/21	05/23
GIMEMA, NCT03367299 / 2017-004251-23: Sequential Chemotherapy and Blinatumomab to Improve MRD Response and Survival in Acute Lymphoblastic Leukemia	Active, not recruiting	2	149	Europe	Chemotherapy + Blinatumomab	Gruppo Italiano Malattie EMatologiche dell'Adulto	Acute Lymphoid Leukemia, Philadelphia Chromosome-Negative B-Cell Precursor	02/24	02/24
NCT02185781: Phase I Study of Adoptive Immunotherapy With Enriched and Expanded Autologous Natural Killer (NK) Cells for Patients With Ph+ Acute Lymphoblastic Leukemia (ALL)	Completed	1	6	Europe	Autologous NK cells infusions	Gruppo Italiano Malattie EMatologiche dell'Adulto	Acute Lymphoblastic Leukemia, Complete Hematologic Remission (CHR), Persistent/Recurrent Minimal Residual Disease (MRD)	11/21	11/21
NCT03318770: Post-Frontline Sequential Treatment of Adult Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia	Recruiting	N/A	60	Europe	Dasatinib and blinatumomab	Gruppo Italiano Malattie EMatologiche dell'Adulto	Acute Lymphoblastic Leukemia	05/24	05/24